Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 18, SUPPLEMENT 2, 110-125, 1996

Hepatitis C virus infection: clinical aspects and treatment with interferon alfa

  • Maureen M. Jonas
    Affiliations
    Center for Childhood Liver Disease, Combined Program in Gastroenterology, Children's Hospital, Boston, Massachusetts U.S.A.
    Department of Pediatrics, Harvard Medical School, Boston, Massachusetts U.S.A.
    Search for articles by this author
DOI:https://doi.org/10.1016/S0149-2918(96)80203-7
Hepatitis C virus infection: clinical aspects and treatment with interferon alfa
Previous ArticleIntravenous immunoglobulin and hepatitis C virus: the boston episode
Next ArticleSecondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Screening for antibodies to hepatitis C virus (HCV) has substantially reduced the risk of HCV infection from transfusion of blood and blood products. Nevertheless, new infections may continue to occur. These infections may be caused by donor infections that escape detection or by insufficient decontamination of blood products during preparation. Frequently, HCV infection becomes chronic, is clinically silent, and can be associated with extrahepatic illnesses and liver cancer. A recent outbreak of HCV infection in patients who received intravenous immunoglobulin has permitted study of this infection in immunocompromised hosts. Some evidence indicates that this infection is more virulent in these patients, and our experience at Children's Hospital, Boston, Massachusetts, substantiates this finding. In this article, epidemiology and modes of transmission of HCV, pathogenesis of HCV infections, differential diagnosis, and clinical features of HCV infection in both children and adults are discussed. Particular attention is given to the serologic findings seen in the spectrum of diseases associated with chronic HCV infection. The mechanisms of action of interferon alfa treatment of HCV infections are discussed. However, results of interferon alfa treatment of patients with HCV infection at Children's Hospital are preliminary.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Alter HJ
        • Purcell RH
        • Shih JW
        • et al.
        Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, and non-B hepatitis.
        NEJM. 1989; 321: 1494-1500
        • Choo Q-L
        • Weiner AJ
        • Overby LR
        • et al.
        Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis.
        Br Med Bull. 1990; 46: 423-441
        • Hopf U
        • Moller B
        • Kuther D
        • et al.
        Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).
        J Hepatol. 1990; 10: 69-76
        • Alter MJ
        • Hadler SC
        • Judson FN
        • et al.
        Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.
        JAMA. 1990; 264: 2231-2235
        • Esteban JI
        • Esteban R
        • Viladomiu L
        • et al.
        Hepatitis C virus antibodies among risk groups in Spain.
        Lancet. 1989; 2: 294-296
        • Zeldis JB
        • Depner TA
        • Kuramoto IK
        • et al.
        The prevalence of hepatitis C virus antibodies among hemodialysis patients.
        Ann Intern Med. 1990; 112: 958-960
        • Niu MT
        • Alter MJ
        • Kristensen C
        • Margolis HS
        Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus.
        Am J Kidney Dis. 1992; 4: 345-352
        • Pereira BJG
        • Milford EL
        • Kirkman RL
        • Levey AS
        Transmission of hepatitis C virus by organ transplantation.
        NEJM. 1991; 325: 454-460
        • Kiyosawa K
        • Sodeyama T
        • Tanada E
        • et al.
        Hepatitis C in hospital employees with needlestick injuries.
        Ann Intern Med. 1991; 115: 367-369
        • Seeff LB
        Hepatitis C from a needlestick injury.
        Ann Intern Med. 1991; 115 (Letter): 411
        • Akahane Y
        • Kojima M
        • Sugai Y
        • et al.
        Hepatitis C virus infection in spouses of patients with type C chronic liver disease.
        Ann Intern Med. 1994; 120: 748-752
        • Kuroki T
        • Nishiguchi S
        • Fukuda K
        • et al.
        Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis.
        Gut. 1993; 34 (Suppl): S52-S53
        • Nagata I
        • Shiraki K
        • Tanimoto K
        • et al.
        Mother-to-infant transmission of hepatitis C virus.
        J Pediatr. 1992; 120: 432-434
        • Inoue Y
        • Miyamura T
        • Unayama T
        • et al.
        Maternal transfer of HCV.
        Nature. 1991; 353 (Letter): 609
        • Ohto H
        • Terazawa S
        • Sasaki N
        • et al.
        Transmission of hepatitis C virus from mothers to infants.
        NEJM. 1994; 330: 744-750
        • Hsu HH
        • Wright TL
        • Luba D
        • et al.
        Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction.
        Hepatology. 1991; 14: 763-767
        • Fried MW
        • Shindo M
        • Fong T-L
        • et al.
        Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C.
        Gastroenterology. 1992; 102: 1306-1308
        • Alter MJ
        Hepatitis C: A sleeping giant?.
        Am J Med. 1991; 91 (Suppl): 112S-115S
        • Lai ME
        • DeVirgilis S
        • Argiolu F
        • et al.
        Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: Comparison between first- and second-generation assay.
        J Pediatr Gastroenterol Nutr. 1993; 16: 458-464
        • Khalifa AS
        • Mitchell BS
        • Watts DM
        • et al.
        Prevalence of hepatitis C viral antibody in transfused and nontransfused Egyptian children.
        Am J Trop Med Hyg. 1993; 49: 316-321
        • Martin P
        • DiBisceglie AM
        • Kassianides C
        • et al.
        Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection.
        Gastroenterology. 1989; 97: 1559-1561
        • Shindo M
        • DiBisceglie AM
        • Cheung L
        • et al.
        Decrease in serum hepatitis C viral DNA during alpha-interferon therapy for chronic hepatitis C.
        Ann Intern Med. 1991; 11: 700-704
        • DiBisceglie AM
        • Hoofnagle JH
        • Krawczynski K
        Changes in hepatitis C virus antigen in liver with antiviral therapy.
        Gastroenterology. 1993; 105: 858-862
        • Mosnier J-F
        • Degott C
        • Marcellin P
        • et al.
        The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study.
        Hepatology. 1993; 17: 366-371
        • Pawlotsky JM
        • Ben Yahia M
        • Andre C
        • et al.
        Immunological disorders in C virus chronic active hepatitis: A prospective case-control study.
        Hepatology. 1994; 19: 841-848
        • Mishiro S
        • Hoshi Y
        • Takeda K
        • et al.
        Non-A, non-B specific antibodies directed at host-derived epitope: Implication for an autoimmune process.
        Lancet. 1990; 336: 1400-1403
        • Yamaguchi K
        • Tanaka E
        • Higashi K
        • et al.
        Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis.
        Gastroenterology. 1994; 106: 1344-1348
        • Weiner AJ
        • Geysen HM
        • Christopherson C
        • et al.
        Immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections.
        Proc Natl Acad Sci USA. 1992; 89: 3468-3472
        • Kumar U
        • Monjardino J
        • Thomas HC
        Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.
        Gastroenterology. 1994; 106: 1072-1075
        • Kuo G
        • Choo Q-L
        • Alter HJ
        • et al.
        An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.
        Science. 1989; 244: 362-364
        • Nakatsuji Y
        • Matsumoto A
        • Tanaka E
        • et al.
        Detection of chronic hepatitis C virus infection by four diagnostic systems: First-generation and second-generation enzyme-linked immunosorbent assay, second-generation recombinant immunoblot assay and nested polymerase chain reaction analysis.
        Hepatology. 1992; 16: 300-305
        • Chen PJ
        • Wang JT
        • Hwang LH
        • et al.
        Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: Putative serologic marker for acute viral infection.
        Proc Natl Acad Sci USA. 1992; 89: 5971-5975
        • Kikuchi T
        • Onji M
        • Michitaka K
        • et al.
        Anti-HCV immunoglobulin M antibody in patients with hepatitis C.
        J Gastroenterology Hepatol. 1992; 7: 246-248
        • Okamoto H
        • Tsuda F
        • Machida A
        • et al.
        Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis C virus infection.
        Hepatology. 1992; 15: 180-186
        • Ebeling F
        • Naukkarinen R
        • Leikola J
        Recombinant immunoblot assay for hepatitis C antibody as a predictor of infectivity.
        Lancet. 1990; 335: 982-983
        • Van der Poel CL
        • Cuypers HTM
        • Reesink HW
        • et al.
        Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.
        Lancet. 1991; 337: 317-319
        • Kanesaki T
        • Kinoshita S
        • Tsujino G
        • et al.
        Hepatitis C virus infection in children with hemophilia: Characterization of antibody response to four different antigens and relationship of antibody response, viremia, and hepatic dysfunction.
        J Pediatr. 1993; 123: 381-387
        • Brechot C
        Polymerase chain reaction for the diagnosis of viral hepatitis B and C.
        Gut. 1993; 34 (Suppl 2): S39-S44
        • Lau JYN
        • Davis GL
        • Kniffen J
        • et al.
        Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.
        Lancet. 1993; 341: 1501-1504
        • Wright TL
        • Hsu H
        • Donegan E
        • et al.
        Hepatitis C virus not found in fulminant non-A, non-B hepatitis.
        Ann Intern Med. 1991; 115: 111-112
        • Liang TJ
        • Jeffers L
        • Reddy RK
        • et al.
        Fulminant or subfulminant non-A, non-B viral hepatitis: The role of hepatitis C and E viruses.
        Gastroenterology. 1993; 104: 556-562
        • Feray C
        • Gigou M
        • Samuel D
        • et al.
        Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver in patients with fulminant hepatitis.
        Gastroenterology. 1993; 104: 549-555
        • Aiyama T
        • Yoshioka K
        • Hirofuji H
        • et al.
        Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
        Dig Dis Sci. 1994; 39: 2244-2249
        • Kakumu S
        • Yoshika K
        • Tanaka K
        • et al.
        Long-term carriage of hepatitis C virus with normal aminotransferases after interferon treatment in patients with chronic hepatitis C.
        J Med Virol. 1993; 41: 65-70
        • Kodama T
        • Tamaki T
        • Katabami S
        • et al.
        Histological findings in asymptomatic hepatitis C virus carriers.
        J Gastroenterol Hepatol. 1993; 8: 403-405
        • Naito M
        • Hayashi N
        • Hagiwara H
        • et al.
        Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels.
        Hepatology. 1994; 19: 871-875
        • Alter HJ
        Descartes before the horse: I clone, therefore I am: The hepatitis C virus in current perspective.
        Ann Intern Med. 1991; 115: 644-649
        • Bortolotti F
        • Vajro P
        • Cadrobbi L
        • et al.
        Cryptogenic chronic liver disease and hepatitis C virus infection in children.
        J Hepatol. 1992; 15: 73-76
        • Bortolotti F
        • Vajro P
        • Barbera C
        • et al.
        Hepatitis C in childhood: Epidemiological and clinical aspects.
        Bone Marrow Transplant. 1993; 12 (Suppl): S21-S23
        • Scheuer PJ
        • Ashrafzadeh P
        • Sherlock S
        • et al.
        The pathology of hepatitis C.
        Hepatology. 1992; 15: 567-571
        • Lefkowitch JH
        • Schiff ER
        • Davis GL
        • et al.
        Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B.
        Gastroenterology. 1993; 104: 556-562
        • Bach N
        • Thung SN
        • Schaffner F
        The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis.
        Hepatology. 1992; 15: 572-577
        • Czaja AJ
        • Carpenter HA
        Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.
        Gastroenterology. 1993; 105: 1824-1832
        • Fried MW
        • Draguesku JO
        • Shindo M
        • et al.
        Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis.
        Dig Dis Sci. 1993; 38: 631-636
        • Lunel F
        • Abuaf N
        • Frangeul L
        • et al.
        Liver/kidney microsome antibody type 1 and hepatitis C virus infection.
        Hepatology. 1992; 16: 630-636
        • Michel G
        • Ritter A
        • Gerken G
        • et al.
        Anti-GOR and hepatitis C virus in autoimmune liver diseases.
        Lancet. 1992; 339: 267-269
        • Tanaka E
        • Kiyosawa K
        • Seki T
        • et al.
        Low prevalence of hepatitis C virus infection in patients with auto-immune hepatitis type 1.
        J Gastroenterol Hepatol. 1993; 8: 442-447
        • Pawlotsky JM
        • Deforges L
        • Bretagne S
        • et al.
        Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.
        Gut. 1993; 34 (Suppl 2): S66-S68
        • Agnello V
        • Chung RT
        • Kaplan LM
        A role for hepatitis C virus infection in type II cryoglobulinemia.
        NEJM. 1992; 327: 1490-1495
        • Lunel F
        • Musset L
        • Cacoub P
        • et al.
        Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage.
        Gastroenterology. 1994; 106: 1291-1300
        • Marcellin P
        • Descamps V
        • Martinot-Peignoux M
        • et al.
        Cryoglobulinemia with vasculitis associated with hepatitis C virus infection.
        Gastroenterology. 1993; 104: 272-277
        • Misiani R
        • Bellavita P
        • Fenili D
        • et al.
        Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.
        NEJM. 1994; 330: 751-756
        • Johnson RJ
        • Gretch DR
        • Yamabe H
        • et al.
        Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.
        NEJM. 1993; 328: 465-470
        • Lacour JP
        • Bodokh I
        • Castanet J
        • et al.
        Porphyria cutanea tarda and antibodies to hepatitis C virus.
        Br J Dermatol. 1993; 128: 121-123
        • Herrero C
        • Vicente A
        • Bruguera M
        • et al.
        Is hepatitis C virus infection a trigger of porphyria cutanea tarda?.
        Lancet. 1993; 341: 788-789
        • DeCastro M
        • Sanchez J
        • Herrera JF
        • et al.
        Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda.
        Hepatology. 1993; 17: 551-557
        • Sheu JC
        • Huang GT
        • Shih LN
        • et al.
        Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma.
        Gastroenterology. 1992; 103: 1322-1327
        • Simonetti RG
        • Camma C
        • Fiorello F
        • et al.
        Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis.
        Ann Intern Med. 1992; 116: 97-102
        • DiBisceglie AM
        • Order SE
        • Klein JL
        • et al.
        The role of chronic viral hepatitis in hepatocellular carcinoma in the United States.
        Am J Gastroenterol. 1991; 86: 335-338
        • Bruix J
        • Barrera JM
        • Calvet X
        • et al.
        Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.
        Lancet. 1989; 2: 1004-1006
        • Colombo M
        • Kuo G
        • Choo QL
        • et al.
        Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.
        Lancet. 1989; 2: 1006-1008
        • Isaacs A
        • Lindenmann J
        Virus interferons. I. The interferon.
        Proc R Soc London B Biol Sci. 1957; 147: 258-267
        • Stewart WE
        2nd ed. The Interferon System. Springer-Verlag, New York, NY1979: 196-222
        • Blanar MA
        • Boettger EC
        • Flavell RA
        Transcriptional activation of HLA-DR alpha by interferon gamma requires a transacting protein.
        Proc Natl Acad Sci USA. 1988; 85: 4672-4676
        • DeMaeyer E
        • DeMaeyer-Guignard J
        Enhanced phagocytic activity of macrophages against Candida albicans. Interferon effects on cellular and humoral immunity.
        in: Baron S Dianzani F Stanton GJ Fleischmann WR The Interferon System: A Current Review to 1987. University of Texas Medical Branch Series, Austin, Texas1987: 327-335
        • Taniguchi T
        Regulation of cytokine gene expression.
        Annu Rev Immunol. 1988; 6: 439-464
        • Peters M
        • Ambrus JL
        • Zhelenznyak A
        • et al.
        Effect of alpha interferon on immunoglobulin synthesis by human B cells.
        J Immunol. 1986; 137: 3153-3157
        • Snapper CM
        • Paul WE
        Interferon gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
        Science. 1987; 236: 944-947
        • Fitzgerald-Bocarsly P
        Human natural interferon-alpha producing cells.
        Pharmacol Ther. 1993; 60: 39-62
        • Zoon KC
        • Arnheiter H
        Studies of the interferon receptors.
        Pharmacol Ther. 1984; 24: 259-278
        • Darnell JE
        • Kerr IM
        • Stark GR
        Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
        Science. 1994; 264: 1415-1421
        • Baglioni C
        • Maroney TA
        • West DK
        2'5'-oligo(A) polymerase activity and inhibition of viral RNA synthesis in interferon treated HeLa cells.
        Biochemistry. 1979; 18: 1765-1770
        • Samuel CE
        The interferon-induced protein P1/eIF-2 alpha kinase.
        in: Baron S Dianzani F Stanton GJ Fleischmann WR The Interferon System: A Current Review to 1987. University of Texas Medical Branch Series, Austin, Texas1987: 373-381
        • Hoofnagle JH
        • Mullen KD
        • Jones DB
        • et al.
        Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon.
        NEJM. 1986; 315: 1575-1578
        • Lau JYN
        • Mizokami M
        • Chno T
        • et al.
        Discrepancy between biochemical and virologic responses to interferon therapy in patients with chronic hepatitis C.
        Lancet. 1993; 342: 1208-1209
        • Tine F
        • Magrin S
        • Craxi A
        • et al.
        Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials.
        J Hepatol. 1991; 13: 192-199
        • Richard O
        • Foberg U
        • Fryden A
        • et al.
        High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks.
        Hepatology. 1994; 19: 280-285
        • Liaw F
        • Sheen I-S
        • Lin S-M
        • et al.
        Effects of prednisone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis.
        Liver. 1993; 13: 46-50
        • Davis GL
        • Balart LA
        • Schiff ER
        • et al.
        Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial.
        NEJM. 1989; 321: 1501-1506
        • DiBisceglie AM
        • Martin P
        • Kassianides C
        • et al.
        Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial.
        NEJM. 1989; 321: 1506-1510
        • Yamada G
        • Takahashi M
        • Tsuji T
        • et al.
        Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C treated with interferon alfa.
        Dig Dis Sci. 1992; 37: 1926-1927
        • Kobayashi Y
        • Watanabe S
        • Konishi M
        • et al.
        Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon.
        J Hepatol. 1992; 16: 138-144
        • Kleter GEM
        • Brouwer JT
        • Heijtink RA
        • et al.
        Detection of hepatitis C virus RNA in patients with chronic hepatitis C infection during and after therapy with alpha interferon.
        Antimicrob Agents Chemother. 1993; 37: 595-597
        • Hayashi J
        • Ohmiya M
        • Kishihara Y
        • et al.
        A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.
        Am J Gastroenterol. 1994; 89: 2151-2156
        • Yun ZB
        • Richard O
        • Chen M
        • et al.
        Serum hepatitis C virus RNA levels in chronic hepatitis C—Importance for outcome of interferon alfa-2b treatment.
        Scand J Infect Dis. 1994; 26: 263-270
        • Causse X
        • Godinot H
        • Chevallier M
        • et al.
        Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A non-B hepatitis.
        Gastroenterology. 1991; 101: 497-502
        • Serfaty L
        • Giral P
        • Loria A
        • et al.
        Factors predictive of the response to interferon in patients with chronic hepatitis C.
        J Hepatol. 1994; 21: 12-17
        • Pagliaro L
        • Craxi A
        • Camma C
        • et al.
        Interferon-alpha for chronic hepatitis C: An analysis of pretreatment predictors of response.
        Hepatology. 1994; 19: 820-828
        • Olynyk JK
        • Reddy RK
        • DiBisceglie AM
        • et al.
        Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.
        Gastroenterology. 1995; 108: 1104-1109
        • Ruiz-Moreno M
        • Rua MJ
        • Castillo I
        • et al.
        Treatment of children with chronic hepatitis C with recombinant interferon-alfa: A pilot study.
        Hepatology. 1992; 16: 882-885
        • Iono R
        • Farriello I
        • Guida S
        • et al.
        Alpha lymphoblastoid interferon therapy in 12 children with chronic hepatitis C.
        Hepatology. 1993; 18 (Abstract): A237
        • Sonnenblick M
        • Rosin A
        Cardiotoxicity and interferon. A review of 44 cases.
        Chest. 1991; 99: 557-561
        • Mattson K
        • Miiranen A
        • Iiavanainen M
        • et al.
        Neurotoxicity of interferon.
        Cancer Treat Rep. 1983; 67: 958-961
        • Guyer DR
        • Tiedeman J
        • Yannuzzi LA
        • et al.
        Interferon-associated retinopathy.
        Arch Ophthalmol. 1993; 111: 350-356
        • Fattovich G
        • Betterle C
        • Brollo L
        • et al.
        Autoantibodies during alfa interferon therapy for chronic hepatitis B.
        Br J Med Virol. 1991; 34: 132-135
        • Black M
        • Petrus M
        Alpha-interferon treatment of chronic hepatitis C: Need for accurate diagnosis in selecting patients.
        Ann Intern Med. 1992; 116: 86-88
        • Silva MO
        • Reddy KJ
        • Jeffers LJ
        • et al.
        Interferon induced chronic active hepatitis.
        Gastroenterology. 1991; 101: 840-842
        • Shindo M
        • DiBisceglie AM
        • Hoofnagle JH
        Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C.
        Gastroenterology. 1992; 102: 1406-1408
        • Lisker-Melman M
        • DiBisceglie AM
        • Usala SJ
        • et al.
        Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa.
        Gastroenterology. 1992; 102: 2155-2160
        • Marcellin P
        • Ponteau M
        • Renard P
        • et al.
        Sustained hypothyroidism induced by recombinant alfa interferon in patients with chronic hepatitis C.
        Gut. 1992; 33: 855-856
        • Gisslinger H
        • Gilly B
        • Woloszczuk W
        • et al.
        Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha.
        Clin Exp Immunol. 1992; 90: 363-367
        • Watanabe U
        • Hashimoto E
        • Hisamitsu T
        • et al.
        The risk factor for development of thyroid disease during interferon alfa therapy for chronic hepatitis C.
        Am J Gastroenterol. 1994; 89: 399-403
        • Lopez-Morante AJ
        • Saez-Royuela F
        • Casanova-Valero F
        • et al.
        Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C.
        Am J Gastroenterol. 1992; 87: 809-810
        • Chazerain P
        • Meyer O
        • Kahn MF
        Rheumatoid arthritis-like disease after alpha-interferon therapy.
        Ann Intern Med. 1992; 116: 427
        • Fabris P
        • Betterle C
        • Florean A
        • et al.
        Development of type I diabetes mellitus during interferon-alfa therapy for chronic HCV hepatitis.
        Lancet. 1992; 340: 548
        • Koivisto VA
        Interferon alfa and development of type I diabetes mellitus.
        Lancet. 1992; 340 (Letter): 1236
        • Funk J
        • Langeland T
        • Schrumpf E
        • et al.
        Psoriasis induced by interferon alpha.
        Br J Dermatol. 1991; 125: 463-465
        • Protzer U
        • Ochsendorf FR
        • Leopolder-Ochsendorf A
        • Holtermuller KH
        Exacerbation of lichen planus during interferon alfa 2b therapy for chronic active hepatitis C.
        Gastroenterology. 1993; 104: 903-905
        • Renault PF
        • Hoofnagle JH
        • Park Y
        • et al.
        Psychiatric complications of long-term interferon alpha therapy.
        Arch Intern Med. 1987; 147: 1577-1580
        • Renault PF
        • Hoofnagle JH
        Side effects of alpha interferon.
        Semin Liver Dis. 1989; 9: 273-277
        • Miller VS
        • Zweiner RJ
        • Fielman BA
        Interferon-associated refractory status epilepticus.
        Pediatrics. 1994; 93: 511-512
        • Graessle D
        • Bonacini M
        • Chen S
        Alpha-interferon and reversible hypertriglyceridemia.
        Ann Intern Med. 1993; 118: 316-317
      123. Data on file. Centers for Disease Control, Atlanta, Georgia19941995

      124. Jonas MM, Baron MJ, Bresee JS, Schneider LS. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics (in press).

        • Webster ADB
        • Lever AML
        Non-A, non-B hepatitis after intravenous gammaglobulin.
        Lancet. 1986; 1 (Letter): 322
        • Björkander J
        • Cunningham-Rundles C
        • Lundin P
        • et al.
        Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency.
        Am J Med. 1988; 84: 107-111
        • Smith MSH
        • Webster ADB
        • Dhillon AP
        Orthotopic liver transplantation for chronic hepatitis in two patients with common variable immunodeficiency.
        Gastroenterology. 1995; 108: 879-884

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(96)80203-7

      Copyright

      © 1996 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX